

P&T Motion History

Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
alirocumab evolocumab inclisiran	After considering the evidence of safety, efficacy and special populations for the treatment of hypercholesterolemia, I move that alirocumab, evolocumab and inclisiran are safe and efficacious for the treatment of their approved indications. Alirocumab and evolocumab can be subject to therapeutic interchange with each other in the Washington preferred drug list. Motion: Barkett 2 nd : Weiland	February 28, 2024	N/A	N/A	Passed unanimous
alirocumab evolocumab	After considering the evidence of safety, efficacy and special populations for the treatment of hypercholesterolemia, I move that alirocumab and evolocumab are safe and efficacious for the treatment of their approved indications. PCSK9 Inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Wiser 2 nd : Harvey	October 16, 2019	NA	Schwilke Storhaug	Passed unanimous

Bold = new this archive report, ineligible to be preferred